Impact of Discontinuing GLP-1 Receptor Agonists for Two Weeks Prior to Upper Endoscopy on the Risk of Gastric Retention

Impact of Discontinuing GLP-1 Receptor Agonists for Two Weeks Prior to Upper Endoscopy on the Risk of Gastric Retention: A Retrospective Observational Study

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07276763

Enrollment

16509

Registered

2025-12-11

Start date

2025-12-10

Completion date

2025-12-15

Last updated

2025-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Retention

Keywords

Glucagon-like peptide-1 receptor agonists, Gastric Retention

Brief summary

A retrospective observational study to explore the impact of discontinuing GLP-1 receptor agonists for two weeks prior to upper endoscopy on the risk of gastric retention

Detailed description

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), including semaglutide, liraglutide, and dulaglutide, are widely used for the management of type 2 diabetes and obesity. These agents improve glycemic control in part by delaying gastric emptying, but this pharmacologic effect may increase the risk of retained gastric contents (RGC) and aspiration during anesthesia or sedation. In 2023, the American Society of Anesthesiologists (ASA) and the American Society for Gastrointestinal Endoscopy (ASGE) issued recommendations to withhold GLP-1RAs before procedures; however, the optimal discontinuation interval remains uncertain. Using the electronic medical record system of Huadong Hospital, this retrospective study analyzed patients who underwent upper endoscopy between August 2023 and May 2025 to examine the association between different GLP-1RA exposure patterns and the risk of RGC, providing evidence to inform optimization of pre-procedural discontinuation strategies.

Interventions

OTHERNo Intervention: Observational Cohort

No Intervention: Observational Cohort

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Undergoing elective upper endoscopy * Complete clinical information available, including endoscopy report, age, sex, BMI, history of diabetes, prior gastric surgery, and gastrointestinal symptom

Exclusion criteria

* Presence of upper gastrointestinal malignancy or obstruction * History of gastric surgery (including ESD, gastrectomy, gastric bypass, etc.) * Emergency endoscopy or non-elective procedures * Missing key clinical information

Design outcomes

Primary

Measure	Time frame
Proportion of gastric retention	Immediately at study initiation

Countries

China

Contacts

Primary ContactDanian Ji, M.D.

arctg4@163.com+86-18019094606

Backup ContactZhiyu Dong, M.D.

18817870866@163.com+86-18817870866

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026